Akeso's Cadonilimab Shows Promise in Pancreatic Cancer, Bolstering Immunotherapy Portfolio
Event summary
- Akeso presented Phase II data (COMPASSION-26 study) for cadonilimab, a PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy for first-line treatment of advanced pancreatic ductal adenocarcinoma (PDAC).
- The combination demonstrated a median progression-free survival (PFS) of 11.1 months and a median overall survival (OS) exceeding 23 months in patients with locally advanced disease.
- Landmark survival rates included a 12-month OS rate of 91.7% and a 24-month OS rate of 44.1% in the locally advanced disease subgroup.
- The objective response rate (ORR) was 33.9% and the disease control rate (DCR) reached 96.4% across the overall study population.
- Cadonilimab received marketing approval in 2022 and is described as a 'cornerstone therapy' in tumor immunotherapy 2.0.
The big picture
Pancreatic cancer remains a devastating disease with limited treatment options, representing a significant unmet medical need. Akeso's cadonilimab combination offers a potential breakthrough, but the long-term durability and broader applicability of these results require further validation. The success of this therapy could solidify Akeso's position as a leader in the burgeoning bispecific antibody market, which is attracting significant investment and competition.
What we're watching
- Regulatory Pathway
- The strength of these Phase II results will likely accelerate discussions with regulatory bodies, but approval hinges on demonstrating similar efficacy in larger, Phase III trials.
- Competitive Landscape
- While cadonilimab is the first approved bispecific antibody for cancer, other companies are aggressively pursuing similar therapies, and Akeso must demonstrate sustained differentiation.
- Commercialization
- The high cost of immunotherapy treatments will necessitate a robust patient access strategy and potentially value-based pricing models to ensure widespread adoption in key markets.
Related topics